TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT01833949

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Unilateral laparoscopic drilling
Description: Unilateral laparoscopic drilling with diathermy adjusted to ovarian volume

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Bilateral laparoscopic drilling
Description: Bilateral laparoscopic drilling with fixed doses energy
Study: NCT01877928

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Boussignac CPAP device
Description: Is a continuous positive airway pressure (CPAP) system marketed in Canada and the US for the treatment of Obstructive Sleep Apnea. The main difference is that this system is portable wheres the standard hospital CPAP is not. This allows for the application immediately post-extubation.

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: standard CPAP
Description: Standard of care postoperative treatment for OSA.
Study: NCT03836261

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Venetoclax
Description: Venetoclax

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Venetoclax
Description: Venetoclax

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Chemoimmunotherapy
Description: fludarabine/cyclophosphamide/rituximab (FCR), bendamustine/rituximab (BR)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Obinutuzumab
Description: Obinutuzumab
Study: NCT02506153

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Biospecimen Collection
Description: Undergo blood sample collection

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Biospecimen Collection
Description: Undergo blood sample collection

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Computed Tomography
Description: Undergo CT scan

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Ipilimumab
Description: Given IV

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Magnetic Resonance Imaging
Description: Undergo MRI

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Magnetic Resonance Imaging
Description: Undergo MRI

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Pembrolizumab
Description: Given IV

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Positron Emission Tomography
Description: Undergo PET scan

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Positron Emission Tomography
Description: Undergo PET scan

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Quality-of-Life Assessment
Description: Ancillary studies

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Quality-of-Life Assessment
Description: Ancillary studies

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Recombinant Interferon Alfa-2b
Description: Given IV and SC
Study: NCT01733004

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MM-141

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MM-141

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MM-141
Study: NCT00433511

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Bevacizumab
Description: Given IV

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Bevacizumab
Description: Given IV

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Cyclophosphamide
Description: Given IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cyclophosphamide
Description: Given IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cyclophosphamide
Description: Given IV

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Doxorubicin Hydrochloride
Description: Given IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Doxorubicin Hydrochloride
Description: Given IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Doxorubicin Hydrochloride
Description: Given IV

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Laboratory Biomarker Analysis
Description: Correlative studies
Study: NCT02043444

Intervention type: RADIATION
Group type: ACTIVE_COMPARATOR
Intervention: FDG PET-CT

Intervention type: RADIATION
Group type: PLACEBO_COMPARATOR
Intervention: FDG PET-CT

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: FDG PET-CT
Study: NCT03692234

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: 125 mg L-homoarginine
Description: capsules for oral supplementation

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: capsules for oral supplementation
Study: NCT00433511

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Laboratory Biomarker Analysis
Description: Correlative studies

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Laboratory Biomarker Analysis
Description: Correlative studies

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Paclitaxel
Description: Given IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Paclitaxel
Description: Given IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Paclitaxel
Description: Given IV

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Placebo Administration
Description: Given IV

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Quality-of-Life Assessment
Description: Ancillary studies (closed as of 5/28/10)
Study: NCT00119977

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: 1 Periacetabular osteotomy
Description: pelvic osteotomy to increase acetabular coverage
Study: NCT00631865

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Melanocyte transplantation
Description: Injection of melanocytes directly in Epidermis
Study: NCT02545413

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Probiotic VSL#3

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Study: NCT03640156

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Oxytocin
Description: A single dose (24IU) of nasal spray (3 puffs of 4IU per nostril) will be administered before the assessment of the neurophysiological measures.

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: A single dose (24IU) of nasal spray (3 puffs of 4IU per nostril) will be administered before the assessment of the neurophysiological measures.
Study: NCT04139174

Intervention type: PROCEDURE
Intervention: first premolar extraction and complete canine retraction.
Description: measurements on panoramic radiograph will be done after first premolar extraction and complete canine retraction.

Intervention type: PROCEDURE
Intervention: first premolar extraction and complete canine retraction.
Description: measurements on panoramic radiograph will be done after first premolar extraction and complete canine retraction.
Study: NCT04396470

Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: tVNS
Description: Participants will be randomized to either the tVNS treatment condition or the sham tVNS (placebo) condition. An identical non-invasive tVNS device will be used in both groups. In the active condition, the device is placed on the external earlobe (tragus), which directly stimulates the vagus nerve. In the sham condition, the device is placed on the external earlobe, providing the same sensations as in the treatment condition, but no stimulation to the vagus nerve. Intervention period: Participants will use the device 1-hr per day for 12 weeks per manufacturer's instructions.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: tVNS
Description: Participants will be randomized to either the tVNS treatment condition or the sham tVNS (placebo) condition. An identical non-invasive tVNS device will be used in both groups. In the active condition, the device is placed on the external earlobe (tragus), which directly stimulates the vagus nerve. In the sham condition, the device is placed on the external earlobe, providing the same sensations as in the treatment condition, but no stimulation to the vagus nerve. Intervention period: Participants will use the device 1-hr per day for 12 weeks per manufacturer's instructions.
Study: NCT01415921

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Pyridostigmine Bromide
Description: 15, 30, and 60 mg tabs, 1 tab every 8 hours for 10 weeks. Forced titration protocol increases dose at 2 week intervals from 15 to 30 to 60 mg as tolerated. Continue maximally tolerated dose for 4 weeks and then downtitrate at weekly intervals (60 to 30 to 15) and then discontinue.
Study: NCT00433511

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Quality-of-Life Assessment
Description: Ancillary studies (closed as of 5/28/10)

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Quality-of-Life Assessment
Description: Ancillary studies (closed as of 5/28/10)
Study: NCT02190331

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Interventional program postural correction training
Description: The postural correction training program was applied in the last 15-20 minutes of each PE class, twice a week, with the supervision and help of the PE teacher.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Control Group physical education classes
Description: Only performed the physical education classes
Study: NCT03204279

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Netupitant
Description: Netupitant 1.33 mg/kg oral suspension up to a maximum of 100 mg

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Palonosetron
Description: Palonosetron 20 μg/kg solution for oral use up to a maximum of 1.5 mg

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Netupitant
Description: Netupitant 4 mg/kg oral suspension up to a maximum of 300 mg

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Palonosetron
Description: Palonosetron 20 μg/kg solution for oral use up to a maximum of 1.5 mg
Study: NCT03811548

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Janagliflozin 25mg
Description: Tablets, Oral, 25 mg, Tablets, Oral, 50 mg

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Janagliflozin 50mg
Description: Tablets, Oral, 25 mg, Once daily, 52 weeks
Study: NCT02188784

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo (for Polysaccharide Iron Complex)
Description: Sugar capsule designed to mimic Polysaccharide Iron Complex.
Study: NCT06181968

Intervention type: DIAGNOSTIC_TEST
Group type: SHAM_COMPARATOR
Intervention: Cardiothoracic ultrasound protocol
Description: Combined echocardiography and lung ultrasound for guiding therapy

Intervention type: DIAGNOSTIC_TEST
Group type: ACTIVE_COMPARATOR
Intervention: Cardiothoracic ultrasound protocol
Description: Combined echocardiography and lung ultrasound for guiding therapy
Study: NCT01425697

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: 2% Chlorhexidine Gluconate cloths
Description: 2% chlorhexidine Gluconate wipes will bw used 12 hours prior to cardiac surgery and then again 3 hours prior to cardiac surgery. Subjects will be randomized to either receive a preoperative phone call reminder or no phone call reminder.

Intervention type: OTHER
Group type: OTHER
Intervention: 2% Chlorhexidine Gluconate cloths
Description: 2% chlorhexidine Gluconate wipes will bw used 12 hours prior to cardiac surgery and then again 3 hours prior to cardiac surgery. Subjects will be randomized to either receive a preoperative phone call reminder or no phone call reminder.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Standard of Care preoperative preparation.
Description: Preoperative standard of care preparation utilized at the clinical site will be used. Subjects will be randomized to either receive a preoperative phone call reminder or no phone call reminder.

Intervention type: OTHER
Group type: OTHER
Intervention: Standard of Care preoperative preparation.
Description: Preoperative standard of care preparation utilized at the clinical site will be used. Subjects will be randomized to either receive a preoperative phone call reminder or no phone call reminder.
Study: NCT00251745

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dexlansoprazole MR
Description: Dexlansoprazole MR 60 mg, capsules, orally, once daily for 4 weeks.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dexlansoprazole MR
Description: Dexlansoprazole MR 90 mg, capsules, orally, once daily for 4 weeks.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Dexlansoprazole placebo-matching capsules, orally, once daily for 4 weeks.
Study: NCT01064739

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Fava beans
Description: Participants will receive 100g of fresh fava beans for breakfast and lunch on one study day and prior to this study day will be restricted to a fixed sodium low monoamine diet
Study: NCT03811548

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo/Janagliflozin
Description: Tablets, Oral, 25 mg, Once daily, 52 weeks
Study: NCT01871129

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Dexmedetomidine
Description: Dexmedetomidine will be diluted into a saline solution to a recommended concentration of 4 micrograms per millilitre. The saline will then be initially administered at the rate of 0.5 micrograms/kg/h and from that point the amount will be reduced to the point where the patient breathes well and is calm (compare dexmedetomidine recommendation at 0.2-1.4 ug/kg/h). The infusion rate will then be approximately 1-10 ml/h for a patient of 80 kgs weight. The exact dosage cannot be predetermined because it differs in each individual. In the control group the infusion speed is matching.

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Saline (placebo)
Description: Saline placebo infusion will be adjusted the same fashion as the active comparator drug.
Study: NCT01064739

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Fixed Sodium Diet
Description: Fixed sodium low monoamine diet
Study: NCT03549910

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: APRVplus protocol
Description: Physiology-driven APRVplus protocol

Intervention type: PROCEDURE
Group type: OTHER
Intervention: Low tidal volume ventilation
Description: Low tidal volume lung protective ventilation
Study: NCT00860899

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: clonidine, levobupivacaine
Description: One hour prior to skin incision, on epidural catheter, patients received 5 µg/kg of clonidine \[Catapres®, Boehringer Ingelheim, Germany\], 7 mL of 0.25% levobupivacaine \[Chirocaine®, Abbott S.p.A., Italy\] or 7 mL of saline.The study was designed to compare clonidine and levobupivacaine, and than both with the control group, in order to asses their analgesic and immunomodulation efficacy.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: clonidine, levobupivacaine
Description: One hour prior to skin incision, on epidural catheter, patients received 5 µg/kg of clonidine \[Catapres®, Boehringer Ingelheim, Germany\], 7 mL of 0.25% levobupivacaine \[Chirocaine®, Abbott S.p.A., Italy\] or 7 mL of saline.The study was designed to compare clonidine and levobupivacaine, and than both with the control group, in order to asses their analgesic and immunomodulation efficacy.
Study: NCT02503488

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Narrative Exposure Therapy for Forensic Offender Rehab
Description: See arm description.
Study: NCT03681626

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: no tracheal suction
Description: No tracheal suctioning during extubation
Study: NCT02503488

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Treatment as Usual
Description: See arm description
Study: NCT03151551

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ixekizumab
Description: Administered SC

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Adalimumab
Description: Administered SC
Study: NCT03165344

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Hydrocortisone sodium succinate mixed with Aluminium Phosphate gel (route of administration)
Description: the test group begin to take hydrocortisone sodium succinate mixed with Aluminium Phosphate gel after 24 hours and gradually reduse the dose.

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Triamcinolone Acetonide (route of administration)
Description: The control group will get local injection of triamcinolone acetonide in wound during the operation.

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Prednisone (route of administration)
Description: The control group begin to take oral prednisone after 24 hours and gradually reduse the dose.
Study: NCT02135419

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: imiquimod
Description: Applied topically

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: fluorouracil
Description: Applied topically

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: infrared photocoagulation therapy
Description: Undergo infrared coagulation
Study: NCT03681626

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: tracheal suction
Description: tracheal suctioning during extubation
Study: NCT02541708

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ferric carboxymaltose
Description: Intravenous Ferric carboxymaltose given at a calculated dose of 20mg/kg body weight in 1-3 infusions according to severity of anemia

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ferrous sulfate + folic acid
Description: Three dried ferrous sulfate and folic acid tablets every morning 30 mins before the meal. If side effects occur the drug may be taken with the meal or in 2 separate doses per day. The treatment will be pursued for 3 months after correction of anemia
Study: NCT00574080

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Interim/Maintenance Dexamethasone
Description: 20 mg Days 1-4 every 3 weeks in the interim between treatment phases and during maintenance

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Interim/Maintenance Dexamethasone
Description: 20 mg Days 1-4 every 3 weeks in the interim between treatment phases and during maintenance

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Induction/Consolidation Dexamethasone
Description: 40 mg Days 1-4

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Induction/Consolidation Dexamethasone
Description: 40 mg Days 1-4

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Induction/Consolidation Cisplatin
Description: 10 mg/m2 by continuous infusion Days 1-4

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Induction/Consolidation Cisplatin
Description: 10 mg/m2 by continuous infusion Days 1-4

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Induction/Consolidation Adriamycin
Description: 10 mg/m2 by continuous infusion Days 1-4

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Induction/Consolidation Adriamycin
Description: 10 mg/m2 by continuous infusion Days 1-4

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: InductionConsolidation Cyclophosphamide
Description: 400 mg/m2 by continuous infusion Days 1-4

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: InductionConsolidation Cyclophosphamide
Description: 400 mg/m2 by continuous infusion Days 1-4

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Induction/Consolidation Etoposide
Description: 40 mg/m2 by continuous infusion Days 1-4

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Induction/Consolidation Etoposide
Description: 40 mg/m2 by continuous infusion Days 1-4

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Induction Pegfilgrastim
Description: 6 mg Days 6 and 13

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Induction Pegfilgrastim
Description: 6 mg Days 6 and 13

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Transplant 1 Dexamethasone
Description: 20 mg Days -4, -3, -2, -1 and +4, +5, +6, and +7

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Transplant 1 Dexamethasone
Description: 20 mg Days -4, -3, -2, -1 and +4, +5, +6, and +7
Study: NCT02135419

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: thermal ablation therapy
Description: Undergo hyfrecation/electrocautery therapy

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: laser therapy
Description: Undergo laser therapy

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: clinical observation
Description: Undergo active monitoring (High Resolution Anoscopy \[HRA\]) with biopsies

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: clinical observation
Description: Undergo active monitoring (High Resolution Anoscopy \[HRA\]) with biopsies

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: laboratory biomarker analysis
Description: Correlative studies

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: laboratory biomarker analysis
Description: Correlative studies